CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
The book “Clinical Trials” by Daniel Schwartz, Robert Flamant and Joseph Lellouch, which described in full detail their distinction between pragmatic and explanatory clinical trials, was published in English in 1980, the year I became the NCIC CTG (now CCTG) director. Their ideas strongly influenced me and my colleagues thinking about how our trials should be designed and conducted.
Breast International Group (BIG) has announced that the second interim analysis of OlympiA trial building on the earlier published results (NEJM) will lead to fewer deaths among patients with germline BRCA-mutated (gBRCA) breast cancer, as the U.S. Food and Drug Administration announced last Friday approval of olaparib for gBRCA breast cancer patients who have had chemotherapy.
We would like welcome a member of the patient representative committee, Sylvie Desmarais who lives in Longueuil, QC and has begun supporting the Breast Disease Site Committee
CCTG PR22: DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.
This is an international trial with sites accruing in Australia, New Zealand, US, UK, Ireland and Canada.
